Back to Search
Start Over
Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
- Source :
-
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2013 Apr 01; Vol. 85 (5), pp. 1262-8. Date of Electronic Publication: 2012 Nov 20. - Publication Year :
- 2013
-
Abstract
- Purpose: To characterize the rates of acute and late duodenal and other gastrointestinal (GI) toxicities among patients treated for cervical and endometrial cancers with extended-field intensity modulated radiation therapy (EF-IMRT) to the paraaortic nodes and to analyze dose-volume relationships of GI toxicities.<br />Methods and Materials: Fifty-three patients with endometrial or cervical cancer underwent EF-IMRT to the paraaortic nodes, of whom 46 met the inclusion criteria for GI toxicity and 45 for duodenal toxicity analysis. The median prescribed dose to the paraaortic nodes was 54 Gy (range, 41.4-65 Gy). The 4 duodenal segments, whole duodenum, small bowel loops, peritoneum, and peritoneum plus retroperitoneal segments of colon were contoured retrospectively, and dosimetric analysis was performed to identify dose-volume relationships to grade ≥3 acute (<90 day) and late (≥90 day) GI toxicity.<br />Results: Only 3/46 patients (6.5%) experienced acute grade ≥3 GI toxicity and 3/46 patients (6.5%) experienced late grade ≥3 GI toxicity. The median dose administered to these 6 patients was 50.4 Gy. One of 12 patients who received 63 to 65 Gy at the level of the renal hilum experienced grade 3 GI toxicity. Dosimetric analysis of patients with and without toxicity revealed no differences between the mean absolute or fractional volumes at any 5-Gy interval between 5 Gy and the maximum dose. None of the patients experienced duodenal toxicity.<br />Conclusions: Treatment of paraaortic nodes with IMRT is associated with low rates of GI toxicities and no duodenal-specific toxicity, including patients treated with concurrent chemotherapy. This technique may allow sufficient dose sparing of the bowel to enable safe dose escalation to at least 65 Gy.<br /> (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Analysis of Variance
Aorta
Cisplatin adverse effects
Cisplatin therapeutic use
Colon radiation effects
Combined Modality Therapy adverse effects
Combined Modality Therapy methods
Dose-Response Relationship, Radiation
Duodenum radiation effects
Endometrial Neoplasms drug therapy
Female
Humans
Intestine, Small radiation effects
Lymphatic Irradiation
Middle Aged
Radiation-Sensitizing Agents adverse effects
Radiation-Sensitizing Agents therapeutic use
Radiotherapy, Intensity-Modulated methods
Retrospective Studies
Uterine Cervical Neoplasms drug therapy
Endometrial Neoplasms radiotherapy
Gastrointestinal Tract radiation effects
Organs at Risk radiation effects
Radiation Injuries pathology
Radiotherapy, Intensity-Modulated adverse effects
Uterine Cervical Neoplasms radiotherapy
Subjects
Details
- Language :
- English
- ISSN :
- 1879-355X
- Volume :
- 85
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- International journal of radiation oncology, biology, physics
- Publication Type :
- Academic Journal
- Accession number :
- 23182395
- Full Text :
- https://doi.org/10.1016/j.ijrobp.2012.10.004